Compounded vs. Branded Oral Minoxidil: A Clinical Comparison

What branded oral minoxidil actually is

Loniten, made by Pfizer, was approved on 18 October 1979 as a new molecular entity [2]. Its labeled indication is hypertension that is symptomatic or associated with target-organ damage and not manageable with maximum doses of a diuretic plus two other antihypertensive drugs [1].

Both Loniten strengths, 2.5 mg and 10 mg, are now marked Discontinued in Drugs@FDA, with a Federal Register determination that they were not discontinued or withdrawn for safety or effectiveness reasons [2]. Generic minoxidil tablets, approved under ANDAs since 1987, remain on the market [2].

What compounded oral minoxidil is

Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they reach patients [3]. They come from two kinds of supplier: traditional pharmacies that compound against a valid patient-specific prescription, and the voluntary outsourcing-facility category, whose members must follow cGMP and are inspected by FDA on a risk-based schedule [3].

The differences that matter

Approval and labeling

Marketed oral tablets have an FDA-approved label, and that label is for severe hypertension [1]. The tablet label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [1]. It also states that extemporaneous (compounded) topical formulations have not been shown to be safe or effective and share the label's contraindications, warnings and adverse reactions, because systemic absorption can occur [1]. That statement covers compounded topical products; it does not describe compounded oral capsules.

Dose

Hair-loss trials have used 1 mg daily [5] and 5 mg daily [6]. Those regimens are off-label and far below the usual antihypertensive range of 10 to 40 mg/day, which starts at 5 mg daily [1].

What the evidence for low-dose oral minoxidil shows

A 2021 review by Randolph and Tosti found 17 studies covering 634 patients published up to April 2020, with androgenetic alopecia the most studied condition. It concluded that oral minoxidil was effective and well tolerated in healthy patients who struggle with topical formulations, and called for larger randomized studies comparing doses [7].

A retrospective multicenter study of 1404 patients (943 women and 461 men, mean age 43) treated for at least 3 months found hypertrichosis in 15.1%, which led to withdrawal in 14 patients (0.5%). Systemic effects were lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3% and insomnia 0.2%, leading to discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed; the study had no control group [4].

A 2025 meta-analysis of uncontrolled studies using 5 mg/day or less found a mean systolic change of -0.13 mm Hg (95% CI -2.67 to 2.41) and diastolic change of -1.25 mm Hg (95% CI -3.21 to 0.71), with heart rate up 2.67 beats/min (0.34 to 5.01). Hypotensive symptoms occurred in 119 patients (5.0%) and no hypotensive episodes were recorded; hypertrichosis was the most frequent side effect and accounted for 34.6% of discontinuations [8].

In a dose-response meta-regression of six studies in androgenetic alopecia, each additional 1 mg/day was associated at 6 months with a mean difference of 47.1 hairs/cm2 in total hair density, 17.9% in hypertrichosis risk and 4.8% in cardiovascular adverse-event risk. The analysis was observational and did not establish causation [9].

Against topical treatment, a double-blind randomized trial in 90 men (68 completed) compared oral 5 mg daily with topical 5% twice daily for 24 weeks and found no statistically significant between-group difference: frontal terminal hair density 3.1 hairs/cm2 (95% CI -18.2 to 21.5; P=.27) and vertex terminal hair density 23.4 hairs/cm2 (95% CI -0.3 to 43.0; P=.09) [6]. A second randomized trial of 65 patients comparing 1 mg/day oral with 5% topical found both groups improved hair diameter over 6 months (P<0.001) with no significant difference between them [5].

Safety

The boxed warning on oral minoxidil tablets describes pericardial effusion, occasionally progressing to tamponade, and exacerbation of angina, and reserves the drug for hypertensive patients who do not respond to a diuretic plus two other antihypertensives; in animals it caused myocardial lesions [1]. The label reports pericardial effusion in about 3% of treated patients not on dialysis [1]. It says the drug must be given under close supervision, usually with a beta blocker to prevent tachycardia and increased myocardial workload and with a diuretic to prevent fluid accumulation [1].

Those statements are written for antihypertensive dosing, which starts at 5 mg daily and usually runs 10 to 40 mg/day [1]. The low-dose hair-loss literature uses 5 mg/day or less [8], but fluid retention, tachycardia and lightheadedness still occurred in the 1404-patient cohort [4].

The only drug interaction named in the oral label is guanethidine, which can produce profound orthostatic hypotension [1]. The label's contraindications are pheochromocytoma and hypersensitivity to any component [1].

Hypertrichosis is the signature effect. The label reports it in about 80% of patients at antihypertensive doses, starting within 3 to 6 weeks at the temples, between the eyebrows and at the sideburns before spreading. Growth stops when the drug is discontinued, but 1 to 6 months may be needed to return to pretreatment appearance, and no endocrine abnormality was found to explain it [1]. At low doses the 1404-patient cohort found 15.1% [4], and each extra 1 mg/day was associated with a mean difference of 17.9% in hypertrichosis risk [9].

The label lists minoxidil as Pregnancy Category C: oral dosing increased fetal resorption in rabbits at five times the maximum recommended human antihypertensive dose, there was no evidence of teratogenic effects in rats and rabbits, and there are no adequate well-controlled studies in pregnant women [1].

What the comparison comes down to

The marketed tablet has an FDA-approved label for severe hypertension only, and hair-loss use of any oral minoxidil is off-label [1]. The randomized and observational data summarized above come from low-dose regimens of 1 mg to 5 mg daily [5][6][8].